Targeting LUADT1-AS-F1 for LUADT Treatment: Understanding the Mechanisms

Target Name: LUADT1

NCBI ID: G106182249

LUADT1

Other Name(s): lung adenocarcinoma associated transcript 1 | Lung adenocarcinoma associated transcript 1

Targeting LUADT1-AS-F1 for LUADT Treatment: Understanding the Mechanisms

Lung adenocarcinoma (LUADT) is a type of cancer that arises from the epithelial cells that line the lungs. It is a highly aggressive and often deadly form of cancer, with a five-year survival rate of just 20%. Despite advances in treatment, the survival rate for advanced stages of LUADT remains poor.

One promising approach to treating LUADT is to target the genetic abnormalities that drive this disease. One such genetic mutation is the lung adenocarcinoma associated transcript 1 (LUADT1) gene.

The LUADT1 gene is located on chromosome 18 and encodes a protein known as LUADT1-AS-F1. This protein is expressed in most tissues of the body and is involved in various cellular processes, including cell signaling, cell adhesion, and cell survival.

In LUADT, LUADT1-AS-F1 mutations have been identified as a key driver of the disease. These mutations occur in the exonic region of the LUADT1 gene, which means that they affect the way the protein is produced and the way it functions.

The LUADT1-AS-F1 gene has been implicated in the development and progression of various types of cancer, including LUADT. Studies have shown that LUADT1-AS-F1 mutations are common in LUADT patients and can be detected using a variety of genetic testing techniques, such as exon sequencing and targeted sequencing arrays.

In addition to their association with LUADT, LUADT1-AS-F1 mutations have also been linked to the development of other types of cancer. For example, studies have shown that LUADT1 mutations are commonly found in colorectal cancer and that these mutations can promote the growth and survival of cancer cells.

Furthermore, LUADT1-AS-F1 mutations have also been associated with poor prognosis in LUADT patients. In a study published in the journal Oncogene, researchers found that patients with LUADT1 mutations had a significantly lower survival rate compared to those without these mutations.

Despite these associations, little is known about the specific mechanisms by which LUADT1-AS-F1 mutations contribute to the development and progression of LUADT. However, research into these mutations is an important step in understanding how this disease develops and could lead to the development of more effective treatments.

In conclusion, LUADT1-AS-F1 is a promising drug target for the treatment of LUADT. The development of LUADT1-AS-F1 mutations has been linked to the growth and survival of LUADT cells, and these mutations have also been associated with poor prognosis in LUADT patients. Further research is needed to understand the specific mechanisms by which LUADT1-AS-F1 mutations contribute to the development and progression of LUADT, and to develop more effective treatments.

Protein Name: Lung Adenocarcinoma Associated Transcript 1

The "LUADT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LUADT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets